8-K: Calidi Biotherapeutics Refiles Financial Statements to Reflect Reverse Stock Split
Current Report (Form 8-K)
Calidi Biotherapeutics refiled its 2023 financial statements to reflect a 1-for-10 reverse stock split effective July 15, 2024.
Summary
- Calidi Biotherapeutics has refiled its consolidated financial statements for the fiscal year ended December 31, 2023.
- The refiling is to give retroactive effect to the company's 1-for-10 reverse stock split of its common stock, which became effective on July 15, 2024.
- The refiled financial statements are attached as exhibits to this report.
- All other information in the original 2023 Annual Report remains unchanged.
Sentiment
Score: 5
Explanation: The document is a routine filing to reflect a reverse stock split, which is neither inherently positive nor negative.
Future Outlook
The Form 8-K is being filed only to reflect the reverse stock split, and all other information in the 2023 Annual Report remains unchanged.
Industry Context
Reverse stock splits are often used by companies to increase their stock price to meet minimum listing requirements or to make the stock more attractive to investors.
Key Dates
| Date | Description |
|---|---|
| December 31, 2023 | Fiscal year end for the consolidated financial statements being refiled. |
| December 12, 2024 | Date of Form S-1 filing, which includes the financial statements incorporated by reference. |
| July 15, 2024 | Effective date of the 1-for-10 reverse stock split. |
| January 10, 2025 | Date of the Form 8-K filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.